Literature DB >> 11432119

Epidemiology and pathophysiology of Alzheimer's disease.

S T DeKosky1.   

Abstract

Researchers in Alzheimer's disease (AD) have made remarkable strides in the past 2 decades in characterizing the disorder, understanding its pathophysiology, and developing models for assessing treatment. With these successes and the promise of others to come, researchers and policy makers alike are keeping a nervous eye on the "demographic clock," which predicts that with the aging of the US population (and indeed the world), a massive increase in the number of AD cases and related dementias will emerge, flooding our medical care system and overwhelming our ability to care for these patients and their caregivers. This article explores some of the data underlying the explosion of AD and discusses the clinical disorder, its manifestations, and our advances in understanding the underlying pathobiology. Our growing knowledge of AD pathophysiology will lead us to the development of more effective medications to slow the progression or even prevent the emergence of this dreaded disorder.

Entities:  

Mesh:

Substances:

Year:  2001        PMID: 11432119     DOI: 10.1016/s1098-3597(01)90045-6

Source DB:  PubMed          Journal:  Clin Cornerstone        ISSN: 1873-4480


  9 in total

1.  Homocysteine and folate deficiency sensitize oligodendrocytes to the cell death-promoting effects of a presenilin-1 mutation and amyloid beta-peptide.

Authors:  Kirk J Pak; Sic L Chan; Mark P Mattson
Journal:  Neuromolecular Med       Date:  2003       Impact factor: 3.843

2.  Involvement of oxidative stress-induced abnormalities in ceramide and cholesterol metabolism in brain aging and Alzheimer's disease.

Authors:  Roy G Cutler; Jeremiah Kelly; Kristin Storie; Ward A Pedersen; Anita Tammara; Kimmo Hatanpaa; Juan C Troncoso; Mark P Mattson
Journal:  Proc Natl Acad Sci U S A       Date:  2004-02-15       Impact factor: 11.205

Review 3.  Alzheimer's Disease Biomarkers Revisited From the Amyloid Cascade Hypothesis Standpoint.

Authors:  Deborah O T Alawode; Nick C Fox; Henrik Zetterberg; Amanda J Heslegrave
Journal:  Front Neurosci       Date:  2022-04-27       Impact factor: 5.152

Review 4.  Hypoxia signaling to genes: significance in Alzheimer's disease.

Authors:  Nicolas G Bazan; Ricardo Palacios-Pelaez; Walter J Lukiw
Journal:  Mol Neurobiol       Date:  2002 Oct-Dec       Impact factor: 5.682

5.  Presenilin-1 mutation sensitizes oligodendrocytes to glutamate and amyloid toxicities, and exacerbates white matter damage and memory impairment in mice.

Authors:  Kirk Pak; Sic L Chan; Mark P Mattson
Journal:  Neuromolecular Med       Date:  2003       Impact factor: 4.103

Review 6.  Mild cognitive impairment: conceptual issues and structural and functional brain correlates.

Authors:  Andrew J Saykin; Heather A Wishart
Journal:  Semin Clin Neuropsychiatry       Date:  2003-01

Review 7.  Cholinesterase inhibitors in Alzheimer's disease and Lewy body spectrum disorders: the emerging pharmacogenetic story.

Authors:  Benjamin Lam; Elizabeth Hollingdrake; James L Kennedy; Sandra E Black; Mario Masellis
Journal:  Hum Genomics       Date:  2009-12       Impact factor: 4.639

8.  An agent-based model to investigate microbial initiation of Alzheimer's via the olfactory system.

Authors:  Shalini Sundar; Carly Battistoni; Ryan McNulty; Fernando Morales; Jonathan Gorky; Henry Foley; Prasad Dhurjati
Journal:  Theor Biol Med Model       Date:  2020-04-15       Impact factor: 2.432

Review 9.  Transitioning from cerebrospinal fluid to blood tests to facilitate diagnosis and disease monitoring in Alzheimer's disease.

Authors:  D O T Alawode; A J Heslegrave; N J Ashton; T K Karikari; J Simrén; L Montoliu-Gaya; J Pannee; A O Connor; P S J Weston; J Lantero-Rodriguez; A Keshavan; A Snellman; J Gobom; R W Paterson; J M Schott; K Blennow; N C Fox; H Zetterberg
Journal:  J Intern Med       Date:  2021-06-26       Impact factor: 8.989

  9 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.